

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 November 2003 (20.11.2003)

PCT

(10) International Publication Number
WO 03/094937 A1

(51) International Patent Classification⁷: A61K 35/16

(21) International Application Number: PCT/KR03/00922

(22) International Filing Date: 9 May 2003 (09.05.2003)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:
10-2002-0025669 9 May 2002 (09.05.2002) KR

(71) Applicant (for all designated States except US): MEDIGENES [KR/KR]; #1822, Hyundai Venture Vill B/D, 713 Suseo-dong, Gangnam-Gu, Seoul 135-539 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEE, Sang-Yup [KR/KR]; #212-702, Expo Apt., 464-1 Jeonmin-dong, Yuseong-gu, Daejeon 305-390 (KR). CHANG, Kyung-Hee [KR/KR]; #1109, LG Palace, 165-8 Donggyo-dong, Mapo-gu, Seoul 121-200 (KR). KEUM, Ki-Chang [KR/KR]; #101-402, Samsung Apt., Sinjeong-dong, Yangcheon-gu, Seoul 158-070 (KR). YOO, Nae-Choon [KR/KR]; #101, Hyundai Villa Da-dong,

45-24 Yeonhui 3-dong, Seodaemun-gu, Seoul 120-113 (KR). YOO, Won-Min [KR/KR]; 48 Dongsomun-dong 3-ga, Seongbuk-gu, Seoul 136-033 (KR). LEE, Gene [KR/KR]; #263-101, Dongil Sweet Apt., Sanghyunni, Suji-eup, Yongin-si, Gyeonggi-do 449-843 (KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF WOUNDS CONTAINING BLOOD PLASMA OR SERUM

(57) Abstract: The present invention relates to a pharmaceutical composition for the treatment of wounds containing blood plasma or serum and a method for treating wounds effectively by applying said composition to the wound site to normalize the tissue-environment around the site.

BEST AVAILABLE COPY

WO 03/094937 A1



— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF WOUNDS
CONTAINING BLOOD PLASMA OR SERUM

TECHNICAL FIELD

5

The present invention relates to the use of blood plasma or serum as an agent for the treatment of wounds. More specifically, the present invention relates to a pharmaceutical composition for the treatment of wounds comprising blood plasma or serum and a method for treating wounds effectively by applying said composition to a wound site to normalize the tissue-environment around the wound site.

BACKGROUND ART

15

The early studies on the treatment of wounds have laid emphasis on a close examination of the functions of the cell stage, i.e., the functions of inflammatory cell and platelet [Allgower M. and Hulliger L., Surgery, 47, 603 (1960); Dicoreto P.E. and Browen-Pope D.F., Proc. Natl. Acad. Sci. USA, 80, 1919 (1983); and Houck J.C. et al., Biochem. Pharmacol., 17, 2081 (1968)].

Recently, growth factors to promote tissue growth have been used in the treatment of wounds such as chronic ulcers. The growth factors stimulate mitogenesis, which is the proliferation of cells such as fibroblast. The growth factors also stimulate angiogenesis, resulting in the ingrowth of new blood vessels. Moreover, the synthesis of collagen and extracellular matrix proteins is stimulated by the growth factors (L. Greenhalgh, J.

Trauma 41:159 (1996)).

Cytokines have been found as growth factors associated with wound healing. Representative examples of such cytokines include basic fibrogrowth factor which is produced by

5 keratinocytes and fibroblasts and promotes the growth of epithelial cells; platelet-derived growth factor(PDGF) which is produced by platelets and the endothelium and other cell types and promotes the abnormal proliferation of epithelial cells in association with epidermal growth factor(EGF); transforming

10 growth factor- β (TGF- β) which is produced by fibroblasts and platelets and promotes the growth of connective tissue; epithelial cell-growth factor which is generated in salivary glands-stimulatory glands and promotes the proliferation of epithelial cells; fibroblast growth factor(FGF); and

15 interleukin-1 which is produced by macrophages and epithelial cells and promotes the growth and mobility of epithelial cells. Becaplermin is a genetically engineered recombinant PDGF that is commercially available as an agent for the treatment of wounds in topical formulations by Johnson & Johnson under the trade

20 name of Regranex[®]. EP 0 575 484 B1 discloses a pharmaceutical composition for the regeneration and repair of mammalian tissues which includes PDGF and dexamethasone. US Patent No. 5,981,606 discloses a pharmaceutical composition for treating wounds which includes TGF- β . WO 96/30038 discloses a pharmaceutical

25 composition for wound healing which includes TGF- β and fibric acid together with antioxidants. US Patent No. 5,183,805 discloses a pharmaceutical composition having the effect of the regeneration of tissues which includes EGF. Japanese Patent No. 05070365 and US Patent No. 6,165,978 disclose wound healing

formulation containing FGF.

Formulations utilizing hyaluronic acid as an active agent have also been reported as being useful in the treatment of skin ulcers (See US Patent No. 5,897,880). Formulations including
5 sodium hyaluronate are marketed by LAM Pharmaceutical Corporation under the trade name of IPN Wound Gel®.

Topically applied fibronectin (glycoprotein found in blood plasma) has also been reported as being useful for increasing the rate of wound healing in corneal wounds (Nishida, Larch
10 Ophthalmology 101:1046 (1983)) and leg ulcers (Wysocki et al., Arch. Dermatol. 124:175 (1988)).

Although such treatments provide some patients with partial wound relief, they need long healing time and fail to exhibit optimum response to the treatment. As wounds, especially,
15 chronic skin ulcers, become serious clinical problems, much effort has been made in finding effective treatments of the wounds. The underlying causes responsible for poor wound closure are complex and still poorly understood.

Therefore, it would be desirable to develop new and
20 improved methods of treating wounds. Use of the present formulations either alone or in combination with various known therapeutic agents overcomes the limitations of the prior art.

SUMMARY OF THE INVENTION

25

The inventors of the present invention have surprisingly found that blood plasma or serum is highly effective in the treatment of wounds. We found that partial defect wounds could be healed in several days after application of the formulation

containing blood plasma or serum according to the present invention. We more surprisingly found that large full defect wounds could be healed within several weeks (about 2 to 6 weeks) after application of the formulation containing blood plasma or serum according to the present invention. These findings represent very significant improvements in both response to treatment and healing time over conventional treatments or other therapeutics currently available or reported until now.

In one aspect, the present invention provides a pharmaceutical composition for wound healing which comprises a pharmaceutically effective amount of blood plasma or serum in combination with a pharmaceutically acceptable carrier.

In another aspect, the present invention provides a method of treating wounds of a subject which comprises applying a pharmaceutical composition comprising a pharmaceutically effective amount of blood plasma or serum to the wound of the subject in need of such treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

20

Fig. 1A is a photograph of the wound tissue of the control rat group on day 7 after it was treated with distilled water (trichrome-stained and viewed with 100X magnification).

Fig. 1B is a photograph of the wound tissue of the test rat group on day 7 after it was treated with the liquid human blood plasma according to the present invention (trichrome-stained and viewed with 100X magnification).

Fig. 2A is a photograph of the wound tissue of the control rat group on day 7 without any treatment after it was wounded

(trichrome-stained and viewed with 100X magnification).

Fig. 2B is a photograph of the wound tissue of the test rat group on day 7 after it was treated with the powdered human blood plasma according to the present invention (trichrome-stained and viewed with 100X magnification).

Fig. 3A is a photograph of the wound tissue of the control rat group on day 7 after it was treated with a water-soluble ointment base alone (trichrome-stained and viewed with 100X magnification).

10 Fig. 3B is a photograph of the wound tissue of the test rat group on day 7 after it was treated with the ointment containing human blood plasma according to the present invention (trichrome-stained and viewed with 100X magnification).

Fig. 4A is a photograph of the wound tissue of the control rat group on day 7 without any treatment after it was wounded (trichrome-stained and viewed with 100X magnification).

Fig. 4B is a photograph of the wound tissue of the test rat group on day 7 after it was treated with the powdered fetal bovine serum (FBS) according to the present invention (trichrome-stained and viewed with 200X magnification).

Fig. 5A is a photograph of the wound tissue of the control rat group on 7 day after it was treated with a water-soluble ointment base alone (trichrome-stained and viewed with 100X magnification).

25 Fig. 5B is a photograph of the wound tissue of the test rat group on day 7 after it was treated with the ointment containing FBS according to the present invention (trichrome-stained and viewed with 100X magnification).

Fig. 6A is a photograph of the wound tissue of the control

rat group on day 7 after it was treated with PDGF ointment (Regranex[®] 0.01%) (trichrome-stained and viewed with 200X magnification).

Fig. 6B is a photograph of the wound tissue of the test rat group on day 7 after it was treated with the ointment containing FBS according to the present invention (trichrome-stained and viewed with 200X magnification).

Fig. 7 is a photograph of rat abdomen with full thickness defect wounds on day 4 and day 7 after it was treated with the PDGF ointment and the ointment containing human blood plasma according to the present invention.

Fig. 8 is a photograph of a second degree burn on day 1, day 2 and day 4 after it was treated with the ointment containing FBS according to the present invention.

Fig. 9 shows a protocol for treatment of chronic wounds according to one or more embodiments of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention generally relates to the use of blood plasma or serum which is useful for treating wounds. The blood plasma or serum used as an active agent in a pharmaceutical composition according to the present invention is highly effective in the treatment of wounds.

Wounds are damaged conditions of living bodies and encompasses cut or disrupted pathological conditions of tissues constituting the internal and external surface of the living body, for example skin, muscle, nervous tissue, bone, soft tissue, inner organs and vascular tissue. The exemplary wounds

include, but are not limited to, contusion or bruise, non-healing traumatic wounds, tissue disruption by irradiation, abrasion, gangrene, laceration, avulsion, penetrated wound, gun shot wound, cutting, burn, frostbite, cutaneous ulcers, xeroderma, skin keratosis, breakage, rupture, dermatitis, dermatophytosis, surgical wounds, wounds caused by vascular disorders, corneal wounds, sores such as pressure sore and bed sore, diabetes and poor circulation-associated conditions diabetic skin erosion, chronic ulcers, suture site following plastic surgery, spinal traumatic wounds, gynecological wounds, chemical wounds and acne. Any damaged or injured part of the living body is within the definition of the wounds. In this respect, the composition comprising blood plasma or serum according to the present invention can be useful for the repair, replacement, alleviation, acceleration, promotion, healing and/or curing of any damaged or injured tissue.

Blood plasma used as an active ingredient in the composition of the present invention typically indicates the straw-colored liquid portion remaining after the material bodies such as blood cells and cell fragments were separated out from the blood. The components of the plasma are well known in the art (Philip Westerman, Plasma Proteins, VII-1 to VIII-13, September 17, 2002; and Wendy Y. Craig, et al., Plasma Proteins Pocket Guide, Foundation for Blood Research - each of which is incorporated by reference in its entirety). Serum is also well defined and generally called as blood plasma without fibrinogen and other clotting factors.

The source of blood plasma or serum used in the composition of the present invention includes humans and

mammalian species, for example, primates, rodents and livestock such as sheep, goat, pig, horse, dog and cattle.

The blood plasma or serum used in the present invention can be readily obtained from the blood using conventional
5 methods such as centrifugation, sedimentation and filtration. Centrifugation would be carried out under any conditions suitable to sediment blood cells and cell fragments, e.g., about 3,000 rpm for about 10 minutes. This condition is sufficient to remove substantially all cell fragments (platelets) as well as
10 red and white blood cells.

The supernatant plasma can be easily separated from the centrifuged cells by standard techniques. Such separation can be achieved using filtration by passing the supernatant plasma through a suitable filter. The filters include a microporous
15 membrane through which proteins are well penetrated.

Blood plasma or serum can be fresh liquid plasma or liquid preparation obtained by centrifugation or sedimentation of whole blood. In addition, blood plasma or serum are known to be reserved in various forms prior to use, including fresh-frozen
20 preparation, cryoprecipitated preparation, lyophilized preparation or concentrated preparation. Such all forms of plasma or serum can be used for the present invention. The fresh-frozen plasma is obtained by centrifuging the blood at about 2,800 rpm for 15 minutes to separate out blood cells and
25 cell fragments and freezing the remaining liquid portion at the temperature of from about -18°C to -40°C . The centrifugation is carried out within six hours from blood collection. For the use, fresh-frozen plasma is thawed out in warm water at the temperature of from about 30°C to 37°C

The cryoprecipitated plasma is obtained by thawing out one unit of a fresh-frozen plasma at the temperature of 4°C to form white precipitate (cold precipitated protein) (including large amounts of factors such as VIII:C, fibrinogen, XIII and fibronectin), isolating the formed precipitate and refreezing it at the temperature of from about -18°C to -40°C. For its use, the cryoprecipitated preparation is thawed out by putting in a refrigerator at the temperature of from 1°C to 6°C overnight. It may be put in a water bath at the temperature of about 4°C to melt down more rapidly. The concentrated plasma is obtained by separating plasma from whole blood, concentrating the separated plasma by mixing it with a thickener such as dextranomer, SEPHADEX, dextramine, polyacrylamide, BIO-GEL P, silica gel, zeolite, DEBRISAN, crosslinked agarose, starch and alginate gel and discarding the remaining thickener.

In one embodiment of the present invention, the blood plasma or serum used for the present invention can be those commercially available, for example, powdered preparations purchased from blood banks. These preparations are derived from units of human blood plasma, which have been tested to elicit no antigen-antibody reaction, for example, non-reactive for antibodies to hepatitis B surface antigen (HBsAg) and hepatitis C (HCV) antibody and negative for antibodies to HIV-1 and HIV-2 viruses. All units of blood plasma or serum used to prepare such preparations are certified free of pathogens.

To reduce the potential risk of transmission of infectious agents, the preparation may be treated with an organic solvent/detergent mixture, for example, tri(n-butyl)/phosphate/polysorbate 80 designed to inactivate enveloped

viruses such as HIV, hepatitis B and HCV. The inactivation and removal of viruses can be enhanced by additionally performing a nanofiltration step.

In another embodiment, the plasma or serum preparation can be prepared through purification, i.e., using solvent detergent and nanofiltration, or pasteurization of a liquid plasma fraction. Alternatively, the whole blood may be purified. The resultant plasma or serum fraction can be powdered by heating, lyophilization or other suitable drying techniques. By way of example only, blood plasma is freeze-dried at the temperature of less than -40°C for several days (e.g., about 7 days). Any conventional techniques and parameters known to those of skill in the art may be used.

In another further embodiment of the present invention, the blood plasma or serum may be in the form of sheet in addition to powder. The sheet is produced by putting the plasma or serum into an appropriate template and dehydrating it. In a still another further embodiment, the sheet can be provided with mechanical strength and/or physical integrity by incorporating a thickening agent or carrier into the blood plasma or serum fraction.

In a preferred embodiment of the present invention, blood plasma or serum is adjusted to acidic pH. We found that the acidified blood or serum has a superior wounds healing efficacy to weakly alkaline plasma or serum. Preferably, the plasma or serum has acidic pH values of from about 3.5 to 6.5. The blood plasma or serum can be acidified using pharmaceutically acceptable inorganic or organic acids. The examples of the pharmaceutically acceptable inorganic acid include, but are not

limited to, hydrochloric acid, nitric acid, sulfuric acid and phosphoric acid. The examples of the pharmaceutically acceptable organic acids include, but are not limited to, formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, benzenesulfonic acid and p-toluenesulfonic acid.

According to the present invention, the blood plasma or serum in the form of liquid or powder can be applied directly onto the wound, i.e., sprinkled over the wound site. The plasma in the form of sheet may be applied over the wound site, which is then dressed suitably to protect the wound and prevent the healing effects of the active ingredient from diminishing. Any commercially available or conventional wound dressing may be used in the present invention. The examples of commercially available wound dressings include, but are not limited to, Compeel, Duoderm, Tagaderm and Opsite.

The composition containing a pharmaceutically effective amount of blood plasma or serum in combination with a pharmaceutically acceptable carrier can be formulated into a variety of forms by means known in the pharmaceutical art. The administration forms include, but are not limited to, conventional dosage forms of external preparation, e.g., liquid paints, sprays, lotions, creams, gels, pastes, liniments, ointments, aerosols, powders and transdermal absorbers. Actual methods for preparing administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's Pharmaceutical Science, 15th Edition, 1975, Mack Publishing Company, Easton,

Pennsylvania 18042 (Chapter 87: Blaug, Seymour), the contents of which are incorporated herein by reference.

In the external preparation of the present invention, suitable carriers can be chosen depending on the dosage forms and include, but are not limited to, hydrocarbons such as vaseline, liquid paraffin, and plasticized hydrocarbon gel(plastibase); animal and vegetable oils such as medium-chain fatty acid triglyceride, lard, hard fat, and cacao oil; higher fatty acid and alcohols and esters thereof such as stearic acid, cetanol, stearyl alcohol, and palmitic acid isopropyl; water-soluble bases such as Macrogol(polyethylene glycol), 1,3-butylene glycol, glycerol, gelatine, white sugar, and sugar alcohol; emulsifiers such as glycerine fatty acid ester, stearic acid polyoxyl, and polyoxyethylene/or curing castor oils; thickeners such as acrylic acid esters, and sodium alginates; propellants such as liquefied petroleum gas, and carbon dioxide; and preservatives such as paraoxybenzoic acid esters. The external preparation of the present invention can be prepared with the aforementioned carriers by methods well-known to those skilled in the art. In addition to said carriers, additives such as stabilizers, pigments, coloring agents, pH adjusting agents, diluents, surfactants, and antioxidants are, if necessary, used. The external preparation of the present invention can be applied to the tropical wound site by conventional methods.

The external preparation according to the present invention may be also used in adhesion onto a solid support such as a wound covering release layer. The adhesion is achieved by saturation of the solid support with the blood plasma or serum fraction, followed by dehydration of the fraction. In one

embodiment of the present invention, the solid support is first coated with an adhesion layer to improve the adhesion of the blood plasma or serum to the solid support. Exemplary adhesion materials include polyacrylate and cyanoacrylate. As such
5 formulation, there is provided a number of commercially available products, including bandage having non-adhesive wound-covering release layer in a perforated plastic film by Smith & Nephew Ltd., BAND-AID in thin strip, patch, spot and thermoplastic strip forms by Johnson & Johnson, CURITY and CURAD
10 ("ouchless" type of bandage) by Kendall Co. (a division of Colgate-Palmolive Company), and STIK-TITE (elastic strip) by American White Cross Labs, Inc.

In one embodiment, the pharmaceutical composition according to the present invention can be formulated into a
15 liquid paint preparation by mixing powdered plasma or serum with physiologic saline at a fixed ratio by volume and adjusting the pH value of the resulting mixture to the range of from 3.5 to 6.5. In another embodiment, the pharmaceutical composition according to the present invention can be formulated into an
20 ointment preparation by mixing the powdered plasma or serum with a water-soluble ointment base and adding physiologic saline to the resulting mixture. Preferably, the pH value of the ointment is adjusted to the range of from 3.5 to 6.5.

According to the present invention, pharmaceutical
25 carriers such as gels or microspheres may be used to promote the wound healing. A variety of microspheres of a polymer as carriers for one or more pharmaceutically or cosmetically active substances is described in U.S. Patent No. 5,264,207, WO 2000/24378, WO96/13164 and WO 94/13333, the entire contents of

which are incorporated herein by reference

The pharmaceutical composition of the present invention can be used to treat a variety of wounds in mammalian animals. Especially, the composition of the present invention is
5 effective for the treatment of non-healing ulcers, including those due to infection, malignancy, large vessel arterial insufficiency, small vessel arterial insufficiency, deep venous blockage or insufficiency, superficial venous
10 insufficiency(varicose veins), lymphatic obstruction, intrinsic circulatory insufficiency, hematologic abnormalities, collagen vascular disorders, radiation dermatitis, trophic causes and the like.

A particular condition that can be treated with the pharmaceutical composition of the present invention includes
15 radiation ulcers. Radiotherapy (for example, in the treatment of cancer) often leads to non-healing skin ulcers. Such ulcers do not respond well to conventional therapies as a result of poor circulation in the radiated tissue and are often treated with low intensity laser irradiation. Radiation ulcers respond well
20 to treatment with the composition comprising the blood plasma or serum according to the present invention. In one embodiment of the present invention, 1 gm dose of the composition containing 5% by weight of blood plasma or serum is applied to a 5 cm² surface area having a thickness of from about 1.5 to 2 mils.

25 The pharmaceutically effective amount of the blood plasma or serum contained in the composition of the present invention refers to an amount which normalizes various cell-activating substances and abnormal cells around the wound site and promotes the wound healing. As one of skill in the art will appreciate,

the amount may vary depending on the wound type being treated, the wound site to be treated, the frequency and time of administration, the route and form of administration, the severity of the wound being treated, the kinds of vehicles, and
5 other factors.

Generally, 2 to 5% by weight of powdered blood plasma or serum are administered per dose. The frequency of administration may range between twice daily and once per week. In a specific embodiment, full thickness defect wounds are treated with from
10 0.01 to 0.1 g/cm² of the pharmaceutical composition of the present invention daily, preferably from 0.02 to 0.09 g/cm², more preferably from 0.02 to 0.07 g/cm².

An exemplary protocol 100 for the treatment of chronic non-healing wound is shown in figure 9. A defect wound is
15 evaluated for determination of suitability for treatment with the active ingredient of the present invention, as shown in step 110 of figure 9. The treatment is appropriate for full thickness defect wounds such as diabetic ulcers, radiation ulcers, pressure sore, third degree burns and other tissue necrosis. The
20 treatment is also appropriate for partial thickness defect wounds such as second degree burns, radiation dermatitis and tissue damaged during dermabrasion.

Once a defect wound is identified as suitable for the treatment according to the invention, the wound is cultured
25 (step 120) to determine whether infection is present. The wound tissue is debrided, if needed. Stage 4 ulcers require debridement; some ulcers may also require deeper surgery. When the ulcers are filled with pus and necrotic debris, application of dextranomer beads or other hydrophilic polymers may hasten

the tissue debridement without surgery. Conservative debridement of necrotic tissue with forceps and scissors should be instituted. Some debridement may be done by cleansing the wound with 1.5% hydrogen peroxide. Wet dressings of water (especially
5 whirlpool baths) will assist in debridging. The granulation that follows removal of necrotic tissue may be satisfactory for skin grafts to cover small areas.

When the culture is positive, the wound is treated for the infection (step 140). Wet dressing including an antibiotic (step
10 145) may be applied prior to blood plasma or serum treatment, or a formulation including powdered plasma or serum in combination with antibiotic is applied (step 148). Exemplary antibiotics include, but are not limited to, penicillinase-resistant penicillin or cephalosporin.

15 Where the culture is negative (step 150), no antibiotics need to be applied, and the wound is treated with the powdered plasma or serum of the invention (step 155).

The powdered plasma or serum is applied to the wound in any of a variety of formulations disclosed herein, and the wound
20 is dressed with conventional wound dressings, such as Compeel, Duoderm, Tagaderm or Opsite wound dressings. Depending on the amount of blood plasma or serum to be administered and the desired release profile of the blood plasma or serum from the pharmaceutical carrier, dressings are changed at intervals
25 ranged between 1 day and 5 days, and may be changed at intervals of 3-4 days. Depending on the extent of damage to the underlying tissue, healing of partial thickness defect wounds is observed in as little as 4 days and of full thickness defect wounds in as little as 2-4 weeks.

The present invention will be more specifically illustrated by the following examples. The following examples are provided to illustrate the present invention, but are not intended to be limited.

5

EXAMPLES

Example 1

Preparation of Blood Plasma in Liquid Phase

10

A human fresh-frozen blood plasma preparation (Central Blood Center of The Republic of Korea National Red Cross, Seoul, Korea), which was certified negative for pathogens including HIV, HCV and hepatitis B, was thawed out at the temperature of 30°C and then mixed with physiologic saline at the ratio by volume of 10:1. The pH of the resulting mixture was adjusted to the value of 5.5 by adding 1N HCl or 1N NaOH with stirring to afford the desired liquid plasma. The pH value was measured using the Orion pH Meter.

20

The remaining blood plasma preparation was cryopreserved in lyophilization bottles, vials, containers or trays, or in other storage bottles.

Example 2

25

Preparation of Lyophilized Blood Plasma in Powder Form

A human fresh-frozen blood plasma preparation (Central Blood Center of The Republic of Korea National Red Cross, Seoul, Korea), which was certified negative for pathogens including HIV,

HCV and hepatitis B, was thawed out at the temperature of 30°C. 500 ml of the resulting liquid blood plasma was placed into a lyophilization bottle and then frozen at the temperature of -80°C (Deep Freezer, Forma Science, Inc., Ohio, USA) for 8 hours. The frozen bottle was mounted on a freeze drying/lyophilization system (Labconco Corporation, Kansas City, Missouri, USA) and lyophilized at the temperature of -48°C for 7 days. All processes were under sterile conditions. 500 ml of liquid blood plasma provides approximately 30 g of lyophilized plasma powder.

10

Example 3

Preparation of Ointment Formulation

5 g of plasma powder prepared as described in Example 2 was mixed with 95 g of water-soluble ointment base (SAM-A base, SAM-A Pharmaceutical Ind. Co., Ltd., Seoul, Korea).

A proper quantity of physiologic saline was added to the resulting mixture with stirring to afford the desired ointment. The ointment base consists of 38 mg of sperm wax, 116 mg of stearyl alcohol, 38 mg of polyethylene glycol 4000, 192 mg of concentrated glycerine, 23 mg of cetanol, proper quantity of purified water, 9 mg of sodium lauryl sulfate, 0.87 mg of paraoxybenzoic acid ethyl and 0.12 mg of paraoxybenzoic acid butyl, based on 1 g of the base.

25

Example 4

Preparation of pH-Adjusted Ointment

5 g of plasma powder prepared as described in Example 2

was mixed with 95 g of a water-soluble ointment base (SAM-A base, SAM-A Pharmaceutical Ind. Co., Ltd., Seoul, Korea). A proper quantity of physiologic saline was added to the resulting mixture to produce an ointment. 1N HCl or 1N NaOH was added to the ointment with stirring to afford the ointment having the pH value of 5.5, which was determined using the Orion pH Meter.

Example 5

Preparation of Lyophilized Blood Plasma in Powder Form

10

500 ml of fetal bovine serum (FBS, Biofluids, Inc., Rockville, MD, USA) having not greater than 0.1 ng/mg of endotoxin capacity and not greater than 30 ng/100ml of hemoglobin capacity was placed into a lyophilization bottle and then frozen at the temperature of -80°C (Deep Freezer, Forma Science, Inc., Ohio, USA) for 6 hours. The frozen bottle was mounted on a freeze drying/lyophilization system (Labconco Corporation, Kansas City, Missouri, USA) and lyophilized at the temperature of -48°C for 7 days to afford the desired lyophilized plasma powder. All processes were under sterile conditions.

Example 6

Preparation of Ointment

25

5 g of plasma powder prepared as described in Example 5 was mixed with 95 g of a water-soluble ointment base (SAM-A Pharmaceutical Ind. Co., Ltd., Seoul, Korea). A proper quantity of physiologic saline was added to the resulting mixture to

produce an ointment. 1N HCl or 1N NaOH was added to the ointment with stirring to afford the desired ointment having a pH 5.5, which was determined using the Orion pH Meter.

5 Example 7

Preparation of Gel

5 parts by weight of plasma powder prepared as described in Example 2 was mixed with 95 parts by weight of an emulsion,
10 which consists of 38 mg of Carbopol ETD 2020, 116 mg of glycerin, 38 mg of propylene glycol, 192 mg of triethanolamine and a proper quantity of purified water, to afford a clear gel with pHs 5.8-6.0. Carbopol ETD 2020 is the mixture of acrylates and C₁₀₋₃₀ alkyl acrylate crosspolymer.

15

Experimental Example 1

Wound-healing Effect of Human Liquid Blood Plasma

The human liquid blood plasma according to the present
20 invention as prepared in Example 1 was applied to a full thickness defect wound to histologically study whether it promotes the formation of granulation tissue on the wound. Ten adult white Sprague-Dawley rats weighing 300-350 mg were used in this experiment.

25

The animal abdomen was completely shaved and subjected to full thickness defect wound with the size of 10 mm x 10 mm. Two wounds were created near both upper limbs, respectively. Likewise, two wounds were created near both lower limbs, respectively. Over each of the two wounds on left side upper and

lower limbs, two layers of gauze with the size of 10 mm x 10 mm wetted by 0.3 ml of liquid blood plasma having a pH 5.5 was applied. As control, over each of the two wounds on right side upper and lower limbs, two layers of gauze with the size of 10 mm x 10 mm wetted by 0.3 mol of distilled water was applied. Then a dressing film (Tagaderm, 3M) was placed over that, which was sewed up on all four sides by 5/0 nylon suture so as not to be detached over the experimental period.

On day 7 after the experiment, wound tissues were taken. Biopsies were 10% neutral buffered formalin fixed for 24 hours and paraffin embedded. The paraffin-embedded biopsies were dissected 4 um in thickness. Sections were stained with hematoxyline-eosine and Masson's trichrome for the visualization of connective tissues. The width of the created granulation tissue was measured from microscopic observation at a magnification of 100x using image analysis program (Image-Pro version 3.0, Microsoft).

The thickness of the granulation tissue layer with only newly formed blood vessels was also measured. The newly formed blood vessels are those that grow from the basement of the tissue to the upper layer, i.e., longitudinally dissected blood vessels in the tissue.

In the case where sections were not of uniform thickness, those having the thickness in the middle of values list were taken. The values obtained were statistically analyzed by Student t-test.

As results, the granulation tissues of the test group were significantly thicker than those of the control group.

The trichrome staining revealed that the test group has

very densely deposited collagen fibers, whereas the control group shows loose distribution of thin collagen fibers. In the test group, new blood vessels of the granulation tissues were created densely between the basement and the upper layer, indicating that the granulation tissues were grown actively. As contrast, the control group shows that a few of new blood vessels were found only at the basement of the granulation tissues, indicating that active development of the granulation tissues has not yet been initiated. See figures 1A and 1B.

10 The thickness of the granulation tissues was measured under the microscope using 40X magnification. The results were statistically analyzed using Student's t-test ($p < 0.05$). The test group showed $168.62 \mu\text{m} \pm 16.06$ which was significantly different from the control group of $59.44 \mu\text{m} \pm 14.42$ ($p < 0.01$). The values
15 were expressed as means \pm standard deviation (SD).

Experimental Example 2

Wound-healing Effect of Human Blood Plasma Powder

20 The human blood plasma powder according to the present invention as prepared in Example 2 was applied to a full thickness defect wound to histologically study whether it promotes the formation of granulation tissue on the wound.

25 In accordance with the same manner as described in the above Experimental Example 1, ten adult white rats were subjected to full thickness defect wound. The two wounds on left side upper and lower limbs were treated with 0.05 g of the human blood plasma powder. As control, the right side two wounds were not treated. Then a dressing film (Tagaderm, 3M) was placed over

the gauzed area, which was sewed up on all four sides by 5/0 nylon suture so as not to be detached over the experimental period.

On day 7 after the experiment, the stained granulation tissue sections were prepared and then the thickness thereof was histologically viewed and measured in accordance with the same manner as described in the above Experimental Example 1. As results, the granulation tissues of the test group were significantly thicker than those of the control group.

In the trichrome staining, whereas the control group showed loosely distributed thin collagen fibers, the test group showed dense deposited collagen fibers. The development of new blood vessels in the granulation tissues of the test group was similar to that of the above Experimental Example 1 in that they were created densely between the basement and the upper layer. See figures 2A and 2B.

The thickness of the granulation tissues was measured under the microscope using 100X magnification. The results were statistically analyzed using Student's t-test ($p < 0.05$). The test group showed $151.62 \mu\text{m} \pm 14.24$ which was significantly different from the control group of $44.24 \mu\text{m} \pm 14.32$ ($p < 0.01$). The values were expressed as means \pm standard deviation (SD).

Experimental Example 3

Wound-healing Effect of Human Blood Plasma-Containing Ointment

The ointment containing human blood plasma according to the present invention as prepared in Example 3 was applied to a full thickness defect wound to histologically study whether it

promotes the formation of granulation tissue on the wound.

In accordance with the same manner as described in the above Experimental Example 1, ten adult white rats were subjected to full thickness defect wound. The two wounds on left side upper and lower limbs were treated with 0.3 g of the ointment of the present invention. As control, the right side two wounds were treated with 0.3 g of SAM-A base (SAM-A Pharmaceutical Ind. Co., Ltd., Seoul, Korea). Then a dressing film (Tagaderm, 3M) was placed over the gauzed area, which was sewed up on all four sides by 5/0 nylon suture so as not to be detached over the experimental period.

On day 7 after the experiment, the stained granulation tissue sections were prepared and then the thickness thereof was histologically viewed and measured in accordance with the same manner as described in the above Experimental Example 1. As results, the granulation tissues of the test group were significantly thicker than those of the control group.

In the trichrome staining, whereas the control group showed loosely distributed thin collagen fibers, the test group showed dense deposited collagen fibers. The development of new blood vessels in the granulation tissues of the test group was similar to that of the above Experimental Example 1 in that they were created densely between the basement and the upper layer. See figures 3A and 3B.

The thickness of the granulation tissues was measured under the microscope using 100X magnification. The results were statistically analyzed using Student's t-test ($p < 0.05$). The test group showed $164.50 \mu\text{m} \pm 17.64$ which was significantly different from the control group of $54.54 \mu\text{m} \pm 10.02$ ($p < 0.01$). The values

were expressed as means +/- standard deviation (SD).

Experimental Examples 4 and 5

Wound-Healing Effect of Fetal Bovine Serum-Containing Ointment 5 and Powder

These experiments were conducted to study the wound-healing effect of blood plasma derived from non-human animals. The abdomens of twenty adult white rats were subjected to full
10 thickness defect wound. In accordance with the same manner as described in the above Experimental Example 2, the first group of 10 animals was treated with fetal bovine serum powder prepared in the above Example 5. In accordance with the same manner as described in the above Experimental Example 3, the
15 second group of 10 animals was treated with fetal bovine serum powder prepared in the above Example 6.

On day 7 after the experiment, the stained granulation tissue sections were prepared and then the thickness thereof was histologically viewed and measured in accordance with the same
20 manner as described in the above Experimental Examples 2 and 3. As results, the granulation tissues of the test group were significantly thicker than those of the control group.

In the trichrome staining, whereas the control group showed loosely distributed thin collagen fibers, the test group
25 showed dense deposited collagen fibers. The development of new blood vessels in the granulation tissues of the test group was similar to that of the above Experimental Examples 2 and 3 in that they were created densely between the basement and the upper layer. See figures 4A, 4B, 5A and 5B.

The thickness of the granulation tissues was measured under the microscope using 100X magnification. The results were statistically analyzed using Student's t-test ($p < 0.05$). For the fetal bovine serum powder, the test group showed $152.62 \mu\text{m} \pm 20.86$ which was significantly different from the control group of $41.20 \mu\text{m} \pm 7.44$ ($p < 0.01$).

For the fetal bovine serum-containing ointment, the test group showed $168.62 \mu\text{m} \pm 19.26$ which was significantly different from the control group of $58.62 \mu\text{m} \pm 7.62$ ($p < 0.01$).

The values were expressed as means \pm standard deviation (SD).

Experimental Examples 6

Comparison of Wound-Healing Effects between Fetal Bovine Serum-Containing Ointment and PDGF Ointment

In this experiment, the wound-healing effect of the fetal bovine serum-containing ointment prepared in the above Example 6 according to the present invention was compared to that of the Regranex[®] (PDGF ointment, Johnson & Johnson) which was first approved as a wound-healing agent by the FDA.

Ten adult white rats were subjected to full thickness defect wound in accordance with the same manner as described in the above Experimental Example 3 except that two full thickness defect wounds were additionally formed along the middle line of the abdomen. While the two wounds on left side upper and lower limbs were treated with 0.3 g of the ointment of the present invention, the two wounds on right side upper and lower limbs were treated with 0.3 g of Regranex[®]. As control, the two wounds

on the middle line of the abdomen were treated with SAM-A base (SAM-A Pharmaceutical Ind. Co., Ltd., Seoul, Korea)

On day 7 after the experiment, the stained granulation tissue sections were prepared and then the thickness thereof was
5 histologically viewed and measured in accordance with the same manner as described in the above Experimental Example 2. As results, the granulation tissues of the Regranex[®]-treated group were thicker than those of the control group but were thinner than those of the test group. Moreover, the granulation tissues
10 of the Regranex[®]-treated group were not dense.

The trichrome staining revealed that the Regranex[®]-treated group generated only few collagen fibers, which were not different from the control group. As contrast, the test group showed densely deposited collagen fibers which were as thick as
15 those of normal dermis and were evenly distributed. For the new blood vessels of the granulation tissues, the Regranex[®]-treated group showed only few longitudinally growing blood vessels. As contrast, the test group showed new blood vessels of the granulation tissues which were densely created between the
20 basement and the upper layer. See figures 6A and 6B.

The thickness of the granulation tissues was measured under the microscope using 200X magnification. The results were statistically analyzed using Student's t-test ($p < 0.05$). The test group showed $168.62\mu\text{m} \pm 13.41$ which was significantly different
25 from the Regranex[®]-treated group of $81.82\mu\text{m} \pm 18.01$ ($p < 0.01$). The values were expressed as means \pm standard deviation (SD).

Experimental Examples 7

Comparison of Wound-Healing Effects between Human Blood Plasma-

Containing Ointment and PDGF Ointment

In this experiment, the wound-healing effect of the human blood plasma-containing ointment prepared in the above Example 3 according to the present invention was compared to that of the Regranex[®] (PDGF ointment, Johnson & Johnson). The abdomen of an adult white rat was subjected to four full thickness defect wounds. As control, the first upper wound was not treated with any agent but was well protected. The second wound was treated with 0.3g of Regranex[®]. Each of the third and fourth wounds was treated with 0.3 g of the human blood plasma-containing ointment.

The third and fourth wounds treated with the human blood plasma-containing ointment were even more quickly healed compared to the first non-treated wound and the second Regranex[®]-treated wound. Figure 7 shows photographs of the wound sites on days 4 and 11 after the initiation of treatment. It can be seen that the plasma-treated wounds (marked as Healadex) showed onset of healing by the 4th day and that by the 11th day, the wounds were almost healed.

20

Experimental Example 8

This experiment demonstrates the healing effect of the FBS-containing ointment as prepared in the above Example 6 according to the present invention on large wounds. The second-degree burn (partial thickness defect wound) was treated with the FBS-containing ointment of the present invention. Figure 8 showed the extent of healing on days 1, 2 and 4 after treatment. The complete wound closure was viewed on day 4 after treatment.

REPLACED BY
ART 36 AACTT

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for the treatment of wounds,
comprising a pharmaceutically effective amount of blood
plasma or serum as an active agent.
2. The pharmaceutical composition according to claim 1,
wherein pH is in the range of 3.5 to 6.6
3. The pharmaceutical composition according to claim 1,
wherein the active agent is derived from livestock.
4. The pharmaceutical composition according to claim 1,
wherein it is topically administered.
5. The pharmaceutical composition according to claim 1, in
the form of creams, ointments, gels, liquids or patches.
6. The pharmaceutical composition according to claim 1,
wherein the wounds include contusion or bruise, non-
healing traumatic wounds, the disruption by irradiation,
abrasion, bone gangrene, laceration, avulsion, penetrated
wound, gun shot wound, cutting, burn, cold sores,
cutaneous ulcers, xeroderma, skin kefatosis, break,
rupture, dermatitis, pain by dermatophyte, wounds by
surgery or by vascular disorder, corneal wounds, pressure
sore, bed sore, certain conditions associated with
diabetes such as diabetic cutaneous disorder and with poor
circulation, chronic ulcers, suture site caused by plastic

REPLACED BY
ART 34 A.1.1


WO 03/094937

PCT/KR03/00922

surgery, spinal traumatic wounds, gynecological wounds,
chemical wounds and acne.


1/15

FIG. 1A




2/15

FIG. 1B




3/15

FIG. 2A



4/15

FIG. 2B



5/15

FIG. 3A


6/15

FIG. 3B



7/15

FIG. 4A




8/15

FIG. 4B



9/15

FIG. 5A




10/15

FIG. 5B




11/15

FIG. 6A




12/15

FIG. 6B



13/15

FIG. 7



14/15

FIG. 8



5


Day 1

Day 2

Day 4

15/15

FIG. 9



INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR03/00922**A. CLASSIFICATION OF SUBJECT MATTER**

IPC7 A61K 35/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7 A61K 35/16

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
delphion on line, kisti on line, pubmed on line**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| X | JP 07-267992 A (HOECHST JAPAN LTD.) 17 OCT. 1997 SEE THE WHOLE DOCUMENT | 1, 3, 6 |
| Y | JP 07-267992 A (HOECHST JAPAN LTD.) 17 OCT. 1997 SEE THE WHOLE DOCUMENT | 2, 4, 5 |
| Y | JP 03-240738 A (HOECHST JAPAN LTD.) 28 NOV. 1991 SEE ABSTRACT | 5 |
| Y | US 5514657 A (YISSUM RES. DEVELOPMENT COM. OF THE HEBREW UNIV.) 17 MAY 1996, SEE ABSTRACT | 4 |
| Y | VOLCHEGORSKII IA ET AL. "Changes in the antioxidative activity of blood serum in inflammation". In; Vopr Med Khim. 1997 Jul.-Aug.; 43(4): SEE ABSTRACT | 1 |

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

25 SEPTEMBER 2003 (25.09.2003)

Date of mailing of the international search report

26 SEPTEMBER 2003 (26.09.2003)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

CHO, Hee Won

Telephone No. 82-42-481-5607



INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR03/00922

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| JP 07-267992 | 17/10/1995 | US 5545720 | 13/08/1996 |
| | | EP 0675135 A3 | 07/02/1996 |
| | | EP 0675135 A2 | 04/10/1995 |
| | | CA2145960 AA | 01/10/1995 |
| | | AU1617495A1 | 12/10/1995 |
| | | AU0689852 B2 | 09/04/1998 |
| JP 03-240738 A | 28/11/1991 | US 5164373 | 17/11/1991 |
| | | PT 0096828 B | 31/07/1991 |
| | | PT 0096828 A | 29/11/1991 |
| | | KR 184008 B | 01/05/1999 |
| | | IE 0910565 A1 | 28/08/1991 |
| | | GR 3017672 T3 | 31/01/1996 |
| | | ES 2077698 T3 | 01/12/1995 |
| | | EP 0499679 A1 | 26/08/1992 |
| | | DK 0499679 T3 | 05/02/1996 |
| | | DE 69113437 T2 | 11/04/1996 |
| | | CA 2036592 AA | 21/08/1991 |
| | | AU 7117891 A1 | 22/08/1991 |
| | | | |
| US 5514657 | 07/05/1996 | ZA 9408690 A | 07/09/1995 |
| | | JP 7206682 A2 | 08/08/1995 |
| | | IL 0107578 A1 | 15/07/1998 |
| | | EP 065321 A1 | 17/05/1995 |
| | | DE 69428020 T2 | 21/03/2002 |
| | | CA 2135139 | 12/05/1995 |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.